Method for detecting rosiverine and related substances by using evaporative light-scattering detector

Through the high-performance liquid-evaporation light scattering detection method, the problem of detection of rosivirin and related substances is solved, high sensitivity and stability detection is achieved, and quality control needs are met.

CN118980765APending Publication Date: 2024-11-19SHANDONG SEQUENTIAL BIOTECHNOLOGY CO LTD
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202411121182.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-15
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

Existing detection methods are difficult to effectively detect rosivirin and its related substances, especially because the ultraviolet absorption of rosivirin is weak and the high boiling point impurities are difficult to vaporize, resulting in unstable and inaccurate detection results.

Method used

Using high-performance liquid-evaporation light scattering detection method, the detection is performed using an evaporation light scattering detector by dissolving the Rosivirin sample in an appropriate solvent, combining specific chromatographic columns and mobile phase conditions, and the area normalization method is used. Calculate impurity content to ensure the accuracy and stability of the detection.

Benefits of technology

It realizes high sensitivity, stability and accuracy detection of rosivirin and related substances, meets the requirements of quality control, and has good reproducibility and resolution.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118980765A_ABST
    Figure CN118980765A_ABST
Patent Text Reader

Abstract

The invention discloses a method for detecting rosiverine and related substances by using an evaporative light-scattering detector. According to the detection method, after a rosiverine sample is dissolved, the rosiverine and the related substances are detected by adopting a high performance liquid chromatography-evaporative light scattering detection method, and the high performance liquid chromatography adopts a chromatographic column taking octadecylsilane chemically bonded silica as a filler. The detection method provided by the invention has the advantages of strong specificity, high stability, good linear relationship, good accuracy and good precision. The detection method is good in reproducibility and separation degree, and can meet the detection requirements and quality control of Rosiverine.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of drug detection, and relates to a method for detecting roxivirine and related substances using an evaporative light scattering detector. Background Art

[0002] At present, the main methods for detecting organic compounds include high performance liquid chromatography (HPLC) and gas chromatography (GC). Among them, HPLC is widely used in the analysis of organic compounds due to its high separation efficiency, high sensitivity and wide applicability. In HPLC, detection is generally carried out by detectors such as ultraviolet-visible (UV-Vis) or mass spectrometry (MS). Although the existing detection methods have met the needs to a certain extent, there are still some problems and limitations. For example, although the MS detector has high sensitivity, its equipment cost is high, the operation is complicated, and it requires specialized operators; and for some compounds that only have terminal absorption, it is difficult to use an ultraviolet-visible (UV-Vis) detector.

[0003] Evaporative light scattering detector (ELSD) is a universal detector. The universal detection method of ELSD eliminates the difficulties commonly found in traditional HPLC detection methods. Unlike UV and fluorescence detectors, the response of ELSD does not depend on the optical properties of the sample. Any sample with a volatility lower than that of the mobile phase can be detected, regardless of its functional groups. ELSD is a highly sensitive detector that improves the sensitivity of detection and can effectively reduce detection costs.

[0004] Rociverine, chemical name: (1R,2R)-1-hydroxy-1,1'-bi(cyclohexyl)-2-carboxylic acid 1-(diethylamino)-2-propyl ester. Rociverine has a highly selective direct smooth muscle relaxant effect and is mainly used to relieve acute and subacute abdominal pain caused by gastrointestinal muscle spasms. The patent CN2024108794008 previously declared by the applicant discloses a method for preparing and splitting a racemic compound of Rociverine. Using pimelic acid as the starting material, it is first esterified with 1-diethylamino-2-propanol. The obtained product is first acylated under the action of thionyl chloride and then a lower alcohol compound (ethanol is used as an example in the reaction equation) is added to form an ester to obtain intermediate 1; an organic base condensation agent is added to intermediate 1 to perform an ester condensation reaction to form intermediate 2; intermediate 2 is added with Grignard reagent cyclohexylmagnesium bromide to perform an addition reaction to generate racemic Rociverine, and then the final chiral compound is obtained by separation and splitting by a chiral preparation column.

[0005]

[0006] The applicant discovered in the research and development of detection methods for Roxivirine and related substances that Roxivirine and impurity 1 (i.e., intermediate 2) do not contain conjugated double bonds and aromatic rings from a structural analysis, but only contain two six-membered alkyl rings and one carbon-oxygen double bond, so the ultraviolet absorption is weak, with ultraviolet absorption only at around 200nm, and it is difficult to detect with an ultraviolet detector. Roxivirine is an oily compound that can be detected by gas chromatography, but the detection result is greatly affected by the vaporization temperature, and due to different product preparation processes, high-boiling impurities may be generated. Since high-boiling impurities are difficult to vaporize, it is difficult to detect them with gas chromatography. Summary of the invention

[0007] In view of the above problems, the present invention provides a method for detecting Roxivirine and related substances using an evaporative light scattering detector. The detection method is to dissolve the Roxivirine sample and then use a high-performance liquid phase-evaporative light scattering detection method to detect Roxivirine and related substances. The detection method of the present invention has strong specificity, high stability, good linear relationship, accuracy and precision. This detection method has good reproducibility and good separation, and can meet the detection requirements and quality control of Roxivirine.

[0008] The technical solution of the present invention is: a method for detecting rosiveverine and related substances by using an evaporative light scattering detector, which is characterized in that after the rosiveverine sample is dissolved, the content of rosiveverine and the content of related substances are detected by using a high performance liquid phase-evaporative light scattering detection method.

[0009] Preferably, the related substances are impurity 1 and total impurities, and the structural formula of impurity 1 is as follows:

[0010]

[0011] The HPLC chromatographic conditions are:

[0012] Chromatographic column: a chromatographic column with octadecylsilane bonded silica as filler (Welch Ultimate LP-C18, 4.6 mm × 300 mm, 3 μm or a chromatographic column with equivalent performance); mobile phase A: 0.01 mol / L trifluoroacetic acid solution; mobile phase B: acetonitrile; flow rate: 0.5 ml / min; column temperature: 25 °C; injection volume: 10 μl; running time: 40 min; gradient elution program is shown in Table 1 below.

[0013] Detector: Evaporative light scattering detector, drift tube temperature 107 ~ 113 ℃.

[0014] Preferably, the solvent for dissolving the Roxivirine sample is methanol.

[0015] Furthermore, the content of roxivirine in the present invention is obtained by external standard method.

[0016] Furthermore, the contents of the related substances in the present invention are obtained by area normalization.

[0017] The technical effects of the present invention are as follows: the detection method of the invention has strong specificity, high stability, good linear relationship, accuracy and precision. The detection method has good reproducibility and good separation, and can meet the detection requirements and quality control of rosiveverine. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] Figure 1 Blank-specificity plot for the evaporative light scattering detector to detect roxivirine and its related substances;

[0019] Figure 2 Specificity-system suitability diagram for the detection of roxivirine and its related substances by evaporative light scattering detector;

[0020] Figure 3 Detection spectrum of the test solution of Roxivirine and its related substances by evaporative light scattering detector;

[0021] Figure 4 Linear profile of roxivirine detected by evaporative light scattering detector;

[0022] Figure 5 Different mobile phase spectra of roxivirine and its related substances detected by evaporative light scattering detector (condition 1);

[0023] Figure 6 Different mobile phases and gradient profiles for detecting roxivirine and its related substances by evaporative light scattering detector (condition 2, gradient program 1);

[0024] Figure 7 Different gradient spectra of roxivirine and its related substances detected by evaporative light scattering detector (gradient program 2). DETAILED DESCRIPTION

[0025] The effects are described below with reference to the embodiments and drawings.

[0026] Example 1

[0027] 1. Instruments and Materials

[0028] Instruments: ELSD6000 detector (Aotai), LC20AT high performance liquid chromatograph (Shimadzu, Japan);

[0029] Reagents: trifluoroacetic acid and acetonitrile are chromatographic grade, and water is ultrapure water. Roxivirine reference substance (Fish Bio, 98.7%); impurity 1 reference substance (homemade, 99.2%)

[0030] 2. Methods and Results

[0031] 2.1 Chromatographic conditions

[0032] Chromatographic column: a chromatographic column filled with octadecylsilane bonded silica gel (Welch Ultimate LP-C18, 4.6 mm × 300 mm, 3 μm or a chromatographic column with equivalent performance); detector: evaporative light detector, drift tube temperature of 107-113°C; carrier gas volume: 3.2 L per minute; Gain: 1; Impactor: Off.

[0033] Mobile phase A: 0.01 mol / L trifluoroacetic acid solution; Mobile phase B: acetonitrile; Flow rate: 0.5 ml / min; Column temperature: 25°C; Injection volume: 10 μl; Running time: 40 min; Gradient elution program is shown in Table 1 below.

[0034] Table 1 Elution gradient

[0035]

[0036] 2.2 Solution preparation

[0037] 2.2.1 System suitability solution preparation

[0038] Preparation of impurity stock solution: Take about 10 mg of impurity 1 reference substance, accurately weigh it, place it in a 20 mL volumetric flask, add methanol and sonicate to dissolve it, and use methanol to make up to volume as the impurity stock solution.

[0039] Preparation of Roxivirine reference solution: Take 50 mg of Roxivirine reference, accurately weigh, place in a 10 mL volumetric flask, add methanol and sonicate to dissolve it, and use methanol to make up to volume as the reference stock solution.

[0040] Preparation of system suitability solution: Take about 50 mg of Roxivirine reference substance, weigh accurately, place in a 10 mL volumetric flask, add methanol and sonicate to dissolve it, add 1 mL of impurity stock solution, make up to volume with methanol, shake well, and use this as system suitability solution. 2.2.2 Preparation of test solution:

[0041] Take about 50 mg of the homemade roxivirine sample, accurately weigh it, put it in a 10 mL volumetric flask, add methanol and ultrasonically dissolve it, dilute it to the fixed volume with methanol, shake it well, and use it as the test solution.

[0042] 2.2.3 Calculation of related substances:

[0043] Take 10μl of system suitability solution and inject it into the liquid chromatograph. The separation between the main peak and the adjacent peaks should be no less than 1.5, and the separation between the known impurities and the adjacent peaks should be no less than 1.5. Accurately measure 10μl of the test solution and inject it into the liquid chromatograph respectively, and record the chromatogram.

[0044] Calculated by area normalization method, known impurities shall not exceed 0.5%, any unknown impurity shall not exceed 0.1%; total impurities shall not exceed 1.0%.

[0045] 2.2.4 Content calculation:

[0046] Take 10 μl of blank solution and inject it into the liquid chromatograph. Accurately measure 10 μl of roxivirine reference solution and 10 μl of self-made test solution, inject them into the liquid chromatograph respectively, and record the spectrum.

[0047] Calculate according to the calculation formula:

[0048] Content (%) = logAX / logAR×logCR / logCX×P (logAX is the logarithmic value of the peak area of ​​rosivereline in the test solution; logAR is the logarithmic value of the peak area of ​​rosivereline in the reference solution; logCR is the logarithmic value of the concentration of rosivereline reference; logCX is the logarithmic value of the test sample concentration; P is the content of rosivereline reference, in %).

[0049] Taking the solution containing this product as an example, the chromatographic conditions shown above were used to perform the following methodological verification on the content:

[0050] 1. Specificity test: The blank solution has no interference at the main peak and the known impurity peak positions, such as Figure 1 As shown. Figure 2 As shown, the separation degree between the main peak and the adjacent peaks in the system suitability solution is ≥3.0, and the separation degree between the known impurities and the adjacent peaks is ≥2.0. The peak purity of the main peak in the peak purity test solution is ≥99.0%, which meets the requirements. The test spectrum of the test solution is as follows Figure 3 shown.

[0051] 2. Linearity: Accurately weigh the Roxivirine reference substance and dilute it into a series of solutions with concentrations of 50.12μg / mL, 501.2μg / mL, 1504μg / mL, 2906μg / mL, 5012μg / mL, and 6014μg / mL for determination. The results are plotted with the logarithmic value of the Roxivirine concentration as the abscissa and the logarithmic value of the Roxivirine peak area as the ordinate to draw the working curve ( Figure 4 ), in the concentration range of 10% to 120%, the concentrations were (50.12μg / mL, 501.2μg / mL, 1504μg / mL, 2906μg / mL, 5012μg / mL, 6014μg / mL), the linear equation of this product was y=1.5379X-0.0105, and the correlation coefficient was r=0.9999 (see Table 2).

[0052] Table 2 Linear data

[0053]

[0054] 3. Detection limit and quantification limit test: Detection limit (2.541 μg / mL): S / N of the main component = 6; Quantification limit (5.310 μg / mL): S / N of the main component = 22.

[0055] 4. Repeatability: Take 6 portions of the test solution, prepare it to a concentration of 5 mg / mL, and test it according to the conditions of the example. The test results are shown in Table 3. The test results show that the RSD of the roxivirine content is ≤1.5% (n=6), and the reproducibility is good.

[0056] Table 3 Repeatability data

[0057]

[0058] 5. Intermediate precision: 12 portions of the test solution were tested according to the conditions of the example. The test results are shown in Table 4. The results show that the RSD of the roxivirine content is ≤2.0%, indicating that the method has good precision.

[0059] Table 4 Intermediate precision data

[0060]

[0061] 6. Accuracy-Recovery: The test solution was added with 80%, 100% and 120% of the test solution of roxivirine reference substance, and the test was carried out according to the conditions of the embodiment. The test results are shown in Table 5. The test results show that the RSD of the recovery of roxivirine is 0.52%, indicating that the method has high accuracy.

[0062] Table 5 Recovery rate data

[0063]

[0064] 7. Solution stability: The test solution was placed at room temperature and sampled and tested at 0h, 2h, 4h, 8h and 24h. The absolute difference in impurity content in the sample solution at each time point was ≤5% compared with that at 0h, and no new impurities ≥0.10% appeared, indicating that the test solution had good stability within 24h. The test results are shown in Table 6.

[0065] Table 6 Solution stability data

[0066]

[0067] 3. Results and Discussion

[0068] 3.1 Screening of different mobile phase conditions and different mobile phase gradients

[0069] Table 7. Screening of different mobile phase conditions.

[0070] Table 7: Different mobile phase conditions

[0071]

[0072]

[0073] According to the spectrum under different mobile phase conditions (such as Figure 5 and 6 ), it can be seen that the mobile phase separation degree of condition 1 does not meet the requirements, and the screening is continued using condition 2.

[0074] The mobile phase gradient screening is shown in Table 8.

[0075] Table 8: Mobile phase gradient screening

[0076]

[0077]

[0078] According to the mobile phase gradient screening ( Figure 6 and 7 ), select the conditions of program gradient 2 as the detection conditions.

[0079] Embodiment 2:

[0080] 1. Apparatus and materials are the same as those in Example 1.

[0081] 2. Chromatographic conditions and detector are the same as in Example 1.

[0082] 3. Solution preparation:

[0083] Preparation of Roxivirine reference solution: Take 50 mg of Roxivirine reference, accurately weigh, place in a 10 mL volumetric flask, add methanol and sonicate to dissolve it, and use methanol to make up to volume as the reference stock solution.

[0084] Preparation of test solution: Take about 50 mg of each of the roxivirine samples SE-20230901, SE-20230902, and SE-20230903, accurately weigh them, place them in a 10 mL volumetric flask, add methanol and ultrasonically dissolve them, dilute to volume with methanol, shake well, and use them as the test solution.

[0085] 4. Determination and calculation of related substances

[0086] Take 10 μl of the prepared solutions of three batches of roxivirine samples respectively, inject them into the liquid chromatograph, and record the spectrum.

[0087] Calculated by area normalization, known impurities shall not exceed 0.5%, any unknown impurities shall not exceed 0.1%, and total impurities shall not exceed 1.0%.

[0088] The test results of relevant substances are shown in Table 9 below.

[0089] Table 9 Related substance test results

[0090]

[0091] 5. Content determination and calculation

[0092] Take 10 μl of the roxivirine reference solution, inject it into the liquid chromatograph, and record the spectrum.

[0093] For each batch of roxivirine samples, solutions were prepared and 10 μl was taken and injected into the liquid chromatograph to record the spectrum.

[0094] Calculated according to the content formula, content (%) = logAX / logAR×logCR / logCX×P (logAX is the logarithmic value of the peak area of ​​rosivereline in the test solution; logAR is the logarithmic value of the peak area of ​​rosivereline in the reference solution; logCR is the logarithmic value of the concentration of rosivereline reference; logCX is the logarithmic value of the test sample concentration; P is the content of rosivereline reference, in %).

[0095] The results of the Roxivirine content test are shown in Table 10 below.

[0096] Table 10 Roxivirine content test results

[0097]

Claims

1. A method for detecting rosiveverine and related substances using an evaporative light scattering detector, characterized in that: After the Roxivirine sample is dissolved, the content of Roxivirine and the content of related substances are detected by high performance liquid phase-evaporative light scattering detection method; the high performance liquid phase uses a chromatographic column with octadecylsilane bonded silica gel as a filler.

2. The method according to claim 1, characterized in that: The related substances are impurity 1 and total impurities. The structural formula of impurity 1 is as follows:

3. The method according to claim 1, characterized in that: The chromatographic conditions of the high performance liquid phase are: Chromatographic column: Welch Ultimate LP-C18; mobile phase A: 0.01 mol / L trifluoroacetic acid solution; mobile phase B: acetonitrile; flow rate: 0.5 ml / min; column temperature: 25°C; gradient elution.

4. The method according to claim 3, characterized in that: The gradient elution conditions are:

5. The method according to claim 1, characterized in that: The evaporative light scattering detector has a drift tube temperature of 107-113°C.

6. The method according to claim 1, characterized in that: The solvent for dissolving the Roxivirine sample is methanol.

7. The method according to any one of claims 1 to 6, characterized in that: The content of roxivirine is obtained by external standard method.

8. The method according to any one of claims 1 to 6, characterized in that: The contents of the related substances are obtained by area normalization.

Citation Information

Patent Citations

  • Preparation and resolution method of rosiverine racemic compound

    CN118812376A